FASN and fatty liver disease: Conversely, glucocorticoids drive the expression of lipogenic genes including fatty-acid synthase (FASN) and acetyl-coA carboxylase 1 (Acaca) [87], stimulate de novo lipogenesis, and block VLDL secretion, thus resulting in hepatic steatosis [88].